MedTrace Logo

Multimodal Investigation of the Neuroprotective Effects of Resveratrol (MINER)

NCT03665740 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2018-09-11

No results posted yet for this study

Summary

Since their return from military service in the 1990-1991 Gulf War, many Veterans have been affected by debilitating symptoms that are not easily explained. A leading hypothesis states that the combination of exposure to toxic chemicals and environmental stressors are responsible for a cluster of debilitating symptoms known as Gulf War Illness (GWI). Research has found that over-the-counter antioxidant supplements such as resveratrol may reverse the damage that causes these debilitating symptoms. Resveratrol is a nutrient found abundantly in the skin of red grapes that is known to have robust antioxidant and anti-inflammatory properties. The investigators predict that resveratrol treatment will improve memory issues, difficulties with thinking and mood problems in Veterans with GWI and that resveratrol will do so with minimal risk.

Conditions

  • Gulf War Illness

Interventions

DRUG

Resveratrol

resveratrol is an OTC supplement

Sponsors & Collaborators

  • Texas A&M University

    collaborator OTHER

  • Baylor University

    collaborator OTHER

  • KR Love Quantitative Consulting and Collaboration

    collaborator OTHER

  • VISN 17 Center of Excellence

    lead FED

Principal Investigators

  • Dena Davidson, Ph.D. · VISN 17 Center of Excellence

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
44 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2022-08-31
Completion
2022-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03665740 on ClinicalTrials.gov